Uniformed Services University of the Health Sciences
Department of Pathology
Institute for Vaccine Research E-mail: firstname.lastname@example.org
4301 Jones Bridge Road, C1094
Bethesda, Maryland 20814-4799
Phone: (301) 295-3490
fax: (301) 295-1640
Fluorescence microscopy for both static and live imaging of the spatiotemporal and functional behavior of distinct cell types in secondary lymphoid organs (e.g. lymph node and spleen) following murine in vivo immunization represents a powerful tool for dissecting the mechanism of a humoral immune response to intact pathogens and vaccines. A major limitation to this approach is the relatively few numbers of B and T cells expressing specificity for any given antigen, and thus the difficulty in finding them in tissue sections. This problem has been largely overcome through the use of B or T cells from mice in which a rearranged B cell receptor (BCR) or T cell receptor (TCR) transgene has been introduced. These mice provide a relatively large source of antigen-specific B or T cells that can be transferred into recipient mice prior to immunization, and then identified either through prior live cell labeling, antibody recognition of allotype differences between donor (transgenic) and recipient mice, fluorescence-labeled intact antigen (B cells) or MHC-peptide tetramers (T cells), or fluorescence-labeled anti-idiotype monoclonal antibodies (B or T cells).
We have been investigating the cellular parameters that underlie the distinct humoral (protein- and polysaccharide-specific) immune responses to intact Streptococcus pneumoniae, capsular type 14 (Pn14) versus a soluble conjugate vaccine of protein and polysaccharide (PPS14) derived from Pn14, or purified PPS14 alone (see Project#2). To better understand the mechanistic parameters underlying these Ig responses we are producing transgenic mice that will express large numbers of 1) B cells specific for PPS14, 2) B cells specific for pneumococcal surface protein A [PspA], and 3) T cells specific for MHC-II-PspA peptide. In addition we have engineered intact Pn14 to express a PspA-cOVA peptide fusion protein in its cell wall in order to utilize T cells from cOVA peptide-specific TCR transgenic mice available in our mouse colony. We have also obtained anti-idiotype mAbs that recognize the PPS14-specific and PspA-specific BCR, respectively, being used to create our transgenic mice, in order to eventually identify the transgenic B cells. The rearranged genomic DNA for the PPS14- and PspA-specific variable heavy and light chain Ig genes have already been cloned and placed in suitable vectors to begin production of transgenic mice.
These transgenic models will allow us to probe more deeply into the mechanisms underlying protein- and polysaccharide-specific humoral immune responses to both whole bacteria and soluble vaccines in an intact murine host and investigate approaches to improve vaccine immunogenicity.